Inclusion Criteria:
* ≥ 18 years old
* Histologically or cytologically confirmed diagnosis of cancer (i.e., Unresectable locally advanced or metastatic non-small-cell lung carcinoma (NSCLC) that had progressed during or after one or more chemotherapy regimens; Metastatic breast cancer; Hormone-refractory prostate cancer; Recurrent or refractory ovarian cancer; Sarcoma)
* ECOG performance status score either 0 or 1
* Willing and able to provide written informed consent
Exclusion Criteria:
Laboratory Values of:
* Absolute neutrophil count \< 2000/µL
* Platelet count \< 100,00/µL
* AST or ALT \> 1.5 x the upper limit of normal
* Alkaline phosphatase \> 5 x the upper limit of normal
* Bilirubin \> ULN
* Creatinine \> 2.0 mg/dL
and
* Peripheral neuropathy NCI CTC Grade 3 or higher
* Chemotherapy, radiation therapy, immunotherapy, or systemic biologic
* anticancer therapy within 21 days before beginning study treatment
* Known history of brain metastases or spinal cord compression
* Uncontrolled hypertension
* Myocardial infarction within 6 months before beginning study treatment
* Unstable angina pectoris, uncontrolled congestive heart failure, or uncontrolled serious arrhythmias
* Known sensitivity to or intolerable adverse effects from taxanes or polysorbate 80
* Known history of porphyria (testing not required at screening)
* Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening)
* Known history of HIV infection (testing not required at screening)
* Female who is pregnant or lactating (pregnancy test is required for all female patients of childbearing potential)
* Female of childbearing potential or sexually active male unwilling to use adequate contraceptive protection
* Physical or mental condition that makes patient unable to complete specified follow-up assessments
